Ovarian mucinous adenocarcinoma is a distinct, relatively uncommon epithelial ovarian cancer histotype characterized by intestinal-type mucinous differentiation. True ovarian primaries are rare (roughly 3% of epithelial ovarian cancers); many apparently mucinous ovarian tumors are metastases from gastrointestinal or other sites, so careful exclusion of a non-ovarian primary is essential. Primary tumors typically arise through a stepwise mucinous cystadenoma -> borderline (atypical proliferative) tumor -> carcinoma sequence. The molecular driver landscape is dominated by early, frequent KRAS mutation driving MAPK-pathway activation, with HER2/ERBB2 amplification in a subset, homozygous CDKN2A loss, and TP53 alterations enriched in invasive/high-grade carcinoma. The histotype is relatively resistant to standard platinum-taxane chemotherapy, motivating interest in HER2-targeted therapy in ERBB2-amplified cases and other targeted approaches. Following the cancer curation guidance, this entry models the mechanism-level disease unit anchored on MONDO with NCIT used for adenocarcinoma morphology.
Ask a research question about Ovarian Mucinous Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Ovarian Mucinous Carcinoma
creation_date: "2026-06-19T00:00:00Z"
description: >-
Ovarian mucinous adenocarcinoma is a distinct, relatively uncommon epithelial
ovarian cancer histotype characterized by intestinal-type mucinous
differentiation. True ovarian primaries are rare (roughly 3% of epithelial
ovarian cancers); many apparently mucinous ovarian tumors are metastases from
gastrointestinal or other sites, so careful exclusion of a non-ovarian primary
is essential. Primary tumors typically arise through a stepwise mucinous
cystadenoma -> borderline (atypical proliferative) tumor -> carcinoma sequence.
The molecular driver landscape is dominated by early, frequent KRAS mutation
driving MAPK-pathway activation, with HER2/ERBB2 amplification in a subset,
homozygous CDKN2A loss, and TP53 alterations enriched in invasive/high-grade
carcinoma. The histotype is relatively resistant to standard platinum-taxane
chemotherapy, motivating interest in HER2-targeted therapy in ERBB2-amplified
cases and other targeted approaches. Following the cancer curation guidance,
this entry models the mechanism-level disease unit anchored on MONDO with NCIT
used for adenocarcinoma morphology.
categories:
- Gynecologic Cancer
- Ovarian Cancer
- Solid Tumor
disease_term:
preferred_term: ovarian mucinous adenocarcinoma
term:
id: MONDO:0005601
label: ovarian mucinous adenocarcinoma
parents:
- ovarian carcinoma
pathophysiology:
- name: Stepwise Mucinous Tumor Progression
description: >-
Primary ovarian mucinous carcinoma develops through a morphologic and
molecular continuum from benign mucinous cystadenoma through atypical
proliferative (borderline) tumor to invasive carcinoma, often coexisting
within the same tumor mass. This stepwise sequence anchors the disease as a
progression-driven epithelial malignancy.
cell_types:
- preferred_term: mucinous (goblet-like) epithelial cell
term:
id: CL:0000160
label: goblet cell
locations:
- preferred_term: ovary
term:
id: UBERON:0000992
label: ovary
downstream:
- target: KRAS Oncogenic Activation
description: >-
KRAS mutation is an early, recurrent event detectable across the
cystadenoma-borderline-carcinoma sequence and seeds the invasive program.
evidence:
- reference: PMID:37664708
reference_title: "Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mucinous ovarian carcinoma (MOC) is a rare histological type of epithelial
ovarian cancer.
explanation: >-
Establishes MOC as a distinct, rare epithelial ovarian carcinoma histotype.
- name: KRAS Oncogenic Activation
description: >-
Activating KRAS mutation (commonly codon 12/13) is the most frequent and
earliest molecular driver in ovarian mucinous tumors, present in roughly
40-50% of invasive carcinomas. It produces constitutive RAS signaling that
feeds the downstream MAPK proliferative cascade.
cell_types:
- preferred_term: epithelial cell
term:
id: CL:0000066
label: epithelial cell
biological_processes:
- preferred_term: Ras protein signal transduction
modifier: INCREASED
term:
id: GO:0007265
label: Ras protein signal transduction
downstream:
- target: MAPK Pathway Activation
description: >-
Mutant KRAS constitutively activates the downstream RAF-MEK-ERK (MAPK)
cascade.
evidence:
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
KRAS mutations are observed in 40–50% of patients, and ERBB2 (human
epidermal growth factor receptor 2, HER2) gene amplification has been
observed in 20–30% of invasive mEOCs
explanation: >-
Human molecular data place KRAS mutation as the dominant recurrent driver
in invasive mucinous ovarian carcinoma.
- name: HER2/ERBB2 Amplification
description: >-
A subset of invasive mucinous carcinomas (about 20-30%) carry ERBB2 (HER2)
gene amplification with receptor overexpression. Amplified HER2 drives
constitutive receptor tyrosine kinase signaling that reinforces MAPK and
PI3K-AKT proliferative output, and defines the principal actionable target
in this histotype.
cell_types:
- preferred_term: epithelial cell
term:
id: CL:0000066
label: epithelial cell
biological_processes:
- preferred_term: ERBB2 signaling pathway
modifier: INCREASED
term:
id: GO:0038128
label: ERBB2 signaling pathway
downstream:
- target: MAPK Pathway Activation
description: >-
Amplified HER2 signaling converges on the MAPK proliferative cascade,
reinforcing the KRAS-driven output in the ERBB2-amplified subset.
evidence:
- reference: PMID:40862711
reference_title: Recent Therapies and Biomarkers in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a unique molecular profile, including frequent KRAS mutations and HER2
amplifications
explanation: >-
Recent review confirms HER2/ERBB2 amplification as a recurrent molecular
feature defining a targetable MOC subset.
- name: MAPK Pathway Activation
description: >-
Constitutive MAPK (RAS-RAF-MEK-ERK) signaling is the convergent proliferative
engine of mucinous ovarian carcinoma, driven by mutant KRAS and reinforced by
HER2 amplification (and occasional BRAF mutation). Sustained MAPK output
promotes uncontrolled proliferation and contributes to the intrinsic
chemoresistance of this histotype.
cell_types:
- preferred_term: epithelial cell
term:
id: CL:0000066
label: epithelial cell
biological_processes:
- preferred_term: MAPK cascade
modifier: INCREASED
term:
id: GO:0000165
label: MAPK cascade
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
downstream:
- target: CDKN2A Loss and Cell Cycle Dysregulation
description: >-
Sustained MAPK-driven proliferation cooperates with loss of cell-cycle
checkpoint control to permit unchecked tumor cell cycling.
evidence:
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
mutations in genes that activate the mitogen activated protein kinase
(MAPK) pathways (such as BRAF, AKT1 and PI3K)
explanation: >-
Supports MAPK-pathway activation as the convergent oncogenic program in
mucinous ovarian carcinoma.
- name: CDKN2A Loss and Cell Cycle Dysregulation
description: >-
Homozygous loss/inactivation of the CDKN2A locus removes p16-mediated cell
cycle checkpoint control, permitting unchecked G1/S progression. CDKN2A loss
is a characteristic lesion of mucinous carcinoma and increases with
progression from benign/borderline to invasive disease.
cell_types:
- preferred_term: epithelial cell
term:
id: CL:0000066
label: epithelial cell
biological_processes:
- preferred_term: cell cycle
modifier: ABNORMAL
term:
id: GO:0007049
label: cell cycle
- preferred_term: cell cycle checkpoint signaling
modifier: ABNORMAL
term:
id: GO:0000075
label: cell cycle checkpoint signaling
downstream:
- target: TP53-Associated Malignant Progression
description: >-
Loss of cell-cycle control sets the stage for acquisition of TP53
alterations that mark the transition to frankly invasive, high-grade
carcinoma.
evidence:
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
mEOC has been associated with a homozygous loss of the cyclin-dependent
kinase inhibitor 2A (CDKN2A) locus
explanation: >-
Establishes homozygous CDKN2A loss as a characteristic lesion of mucinous
ovarian carcinoma.
- name: TP53-Associated Malignant Progression
description: >-
TP53 mutation is enriched in invasive/high-grade mucinous carcinoma relative
to benign and borderline lesions (reported in roughly 16-52% of mEOCs) and
is associated with advanced FIGO stage, residual disease, and poorer overall
survival. Loss of p53 tumor-suppressor function marks the progression to
invasive carcinoma.
cell_types:
- preferred_term: epithelial cell
term:
id: CL:0000066
label: epithelial cell
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
downstream:
- target: Invasive Mucinous Carcinoma
description: >-
Accumulated KRAS/MAPK activation, CDKN2A loss, and TP53 alteration produce
a frankly invasive mucinous adenocarcinoma.
evidence:
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
only 16–52% of mEOCs have a TP53 mutation compared to 99% of HGSOCs
explanation: >-
Quantifies TP53 mutation frequency in mEOC and contrasts it with the
near-universal TP53 mutation of high-grade serous carcinoma.
- name: Invasive Mucinous Carcinoma
description: >-
The convergent endpoint of the mucinous oncogenic program is an invasive
intestinal-type mucinous adenocarcinoma of the ovary, typically presenting as
a large, multilocular, usually unilateral ovarian mass. Advanced disease may
spread to the peritoneum. This invasive carcinoma is the substrate for the
histotype's characteristic chemoresistance.
cell_types:
- preferred_term: mucinous (goblet-like) epithelial cell
term:
id: CL:0000160
label: goblet cell
locations:
- preferred_term: ovary
term:
id: UBERON:0000992
label: ovary
- preferred_term: peritoneum
term:
id: UBERON:0002358
label: peritoneum
downstream:
- target: Intrinsic Chemoresistance
description: >-
Invasive mucinous carcinoma is intrinsically poorly responsive to standard
platinum-taxane chemotherapy.
evidence:
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
advanced mEOC (Stage III/IV) has a very dismal one, with a median overall
survival (OS) of 12–14 months, well below the 37–42 months OS observed in
patients with non-mucinous epithelial ovarian cancer
explanation: >-
Human outcomes data establish the poor survival of advanced invasive
mucinous ovarian carcinoma relative to other histotypes.
- name: Intrinsic Chemoresistance
description: >-
Unlike high-grade serous ovarian carcinoma, mucinous ovarian carcinoma is
intrinsically resistant to platinum-based chemotherapy, with only about 30%
of patients responding to first-line therapy versus about 70% of high-grade
serous patients. This relative chemoresistance underlies the poor outcomes of
advanced disease and motivates targeted-therapy approaches.
cell_types:
- preferred_term: epithelial cell
term:
id: CL:0000066
label: epithelial cell
evidence:
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
only ≈30% of patients respond to first line therapy, whereas 70% of
high-grade serous ovarian cancer (HGSOC) patients do
explanation: >-
Quantifies the intrinsic platinum-chemoresistance of mucinous ovarian
carcinoma relative to high-grade serous carcinoma.
- reference: PMID:37664708
reference_title: "Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It has poor response to conventional platinum-based chemotherapy regimens
and PARPi-based maintenance treatment, resulting in short survival and poor
prognosis in advanced-disease patients.
explanation: >-
Independent review confirms poor response to standard chemotherapy and the
resulting poor advanced-stage prognosis.
histopathology:
- name: Ovarian Mucinous Adenocarcinoma Morphology
finding_term:
preferred_term: Ovarian Mucinous Adenocarcinoma
term:
id: NCIT:C5243
label: Ovarian Mucinous Adenocarcinoma
frequency: VERY_FREQUENT
description: >-
The tumor shows intestinal-type mucinous adenocarcinoma morphology with
malignant glandular epithelium containing abundant intracytoplasmic mucin,
typically arising in a large multilocular cystic ovarian mass and showing
expansile or infiltrative invasion patterns.
evidence:
- reference: PMID:33919741
reference_title: "What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The fifth edition of the World Health Organization classification of tumors
of the female genital tract divides ovarian carcinomas into at least five
main and distinct types of ovarian carcinomas: high-grade serous carcinoma,
low-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma,
and mucinous carcinoma.
explanation: >-
WHO 2020 classification establishes mucinous carcinoma as a distinct
principal ovarian carcinoma histotype defined by morphology and molecular
features.
phenotypes:
- category: Neoplastic
name: Ovarian Carcinoma
frequency: VERY_FREQUENT
diagnostic: true
description: >-
The disease presents as a malignant epithelial ovarian carcinoma with
mucinous (intestinal-type) differentiation, classified within epithelial
ovarian cancer histology workups.
phenotype_term:
preferred_term: Ovarian carcinoma
term:
id: HP:0025318
label: Ovarian carcinoma
- category: Neoplastic
name: Ovarian Mass
frequency: FREQUENT
description: >-
Primary mucinous ovarian carcinoma typically presents as a large,
multilocular, usually unilateral ovarian neoplasm; tumor size >10 cm and
unilateral presentation favor a primary ovarian origin over metastasis.
phenotype_term:
preferred_term: Ovarian neoplasm
term:
id: HP:0100615
label: Ovarian neoplasm
- category: Abdominal
name: Abdominal Distension
description: >-
A growing pelvic/abdominal mass commonly produces abdominal distension; MOC
often presents with non-specific symptoms such as distension and pain.
phenotype_term:
preferred_term: Abdominal distention
term:
id: HP:0003270
label: Abdominal distention
notes: >-
Abdominal distension is a common non-specific presenting feature of the
enlarging ovarian mass; no symptom-specific abstract snippet is available in
the cited sources, so it is recorded without an evidence citation.
- category: Abdominal
name: Abdominal Pain
description: >-
Abdominal/pelvic pain is among the common non-specific presenting symptoms of
mucinous ovarian carcinoma.
phenotype_term:
preferred_term: Abdominal pain
term:
id: HP:0002027
label: Abdominal pain
genetic:
- name: KRAS
association: Most frequent and earliest recurrent activating somatic driver mutation
gene_term:
preferred_term: KRAS
term:
id: hgnc:6407
label: KRAS
evidence:
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
KRAS mutations are observed in 40–50% of patients, and ERBB2 (human
epidermal growth factor receptor 2, HER2) gene amplification has been
observed in 20–30% of invasive mEOCs
explanation: >-
Identifies KRAS as the dominant recurrent driver mutation of mucinous
ovarian carcinoma.
notes: >-
KRAS mutation is an early event detectable across the
cystadenoma-borderline-carcinoma sequence and is associated with relative
platinum resistance.
- name: ERBB2
association: HER2 gene amplification/overexpression in a targetable subset
gene_term:
preferred_term: ERBB2
term:
id: hgnc:3430
label: ERBB2
evidence:
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ERBB2 (human epidermal growth factor receptor 2, HER2) gene amplification
has been observed in 20–30% of invasive mEOCs
explanation: >-
Quantifies ERBB2/HER2 amplification frequency, the principal actionable
molecular target in mucinous ovarian carcinoma.
notes: >-
ERBB2 amplification defines the subset eligible for HER2-targeted therapy.
- name: CDKN2A
association: Recurrent homozygous loss/inactivation of the tumor suppressor locus
gene_term:
preferred_term: CDKN2A
term:
id: hgnc:1787
label: CDKN2A
evidence:
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
mEOC has been associated with a homozygous loss of the cyclin-dependent
kinase inhibitor 2A (CDKN2A) locus
explanation: >-
Establishes homozygous CDKN2A loss as a characteristic recurrent lesion of
mucinous ovarian carcinoma.
- name: TP53
association: Mutation enriched in invasive/high-grade carcinoma and associated with progression
gene_term:
preferred_term: TP53
term:
id: hgnc:11998
label: TP53
evidence:
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
only 16–52% of mEOCs have a TP53 mutation compared to 99% of HGSOCs
explanation: >-
Quantifies TP53 mutation frequency in mEOC; TP53 alteration is enriched in
invasive/high-grade disease and marks malignant progression.
notes: >-
TP53 mutation is associated with advanced FIGO stage, residual disease, and
poorer overall survival.
treatments:
- name: Cytoreductive Surgery
description: >-
Complete surgical resection (R0; total abdominal hysterectomy, bilateral
salpingo-oophorectomy, omentectomy, peritoneal staging) is the cornerstone of
management. Intraoperative cyst rupture should be avoided to limit peritoneal
mucin dissemination.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: PMID:36603894
reference_title: "Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Despite being a chemoresistant tumour type, surgical resection and
chemotherapy are still the current standard for management.
explanation: >-
Confirms surgical resection as a current standard-of-care component of
management for mucinous ovarian carcinoma.
- name: First-Line Platinum-Taxane Chemotherapy
description: >-
Carboplatin plus paclitaxel remains the conventional first-line chemotherapy
backbone, though advanced mucinous ovarian carcinoma responds poorly relative
to other histotypes (about 30% response vs about 70% in high-grade serous).
treatment_term:
preferred_term: chemotherapy
term:
id: MAXO:0000647
label: chemotherapy
therapeutic_agent:
- preferred_term: carboplatin
term:
id: CHEBI:31355
label: carboplatin
- preferred_term: paclitaxel
term:
id: CHEBI:45863
label: paclitaxel
evidence:
- reference: PMID:36603894
reference_title: "Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Despite being a chemoresistant tumour type, surgical resection and
chemotherapy are still the current standard for management.
explanation: >-
Confirms chemotherapy as a standard management component despite the
histotype's chemoresistance.
- reference: PMID:32183025
reference_title: Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
patients are still treated as a homogeneous group with cyto-reductive
surgery followed by platinum/taxane doublet therapy
explanation: >-
Identifies the platinum/taxane doublet as the standard first-line regimen
applied to mucinous ovarian carcinoma.
- name: HER2-Targeted Therapy
description: >-
For the ERBB2 (HER2)-amplified subset, HER2-directed agents such as
trastuzumab (and HER2 antibody-drug conjugates) are a rational targeted
therapy, supported by case reports of dramatic responses and active clinical
investigation.
therapeutic_modality: MONOCLONAL_ANTIBODY
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: trastuzumab
term:
id: CHEBI:231601
label: trastuzumab
target_mechanisms:
- target: HER2/ERBB2 Amplification
treatment_effect: INHIBITS
description: >-
HER2-directed agents (trastuzumab and HER2 antibody-drug conjugates)
target the amplified ERBB2 (HER2) receptor in the HER2-positive mucinous
ovarian carcinoma subset, blocking its downstream proliferative signaling.
evidence:
- reference: PMID:40862711
reference_title: Recent Therapies and Biomarkers in Mucinous Ovarian Carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Recent advancements in targeted therapy, such as HER2 inhibitors and
KRASG12C inhibitors, offer promising avenues for personalized treatment.
explanation: >-
Supports HER2-targeted therapy as an emerging targeted approach for the
HER2-amplified mucinous ovarian carcinoma subset.
- reference: PMID:36603894
reference_title: "Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Targeted therapies identified in this review that warrant further
investigations are bevacizumab, trastuzumab, nintedanib, AZD1775,
sunitinib, cediranib and pazopanib.
explanation: >-
Clinical-trial review identifies trastuzumab among the targeted therapies
warranting further investigation in mucinous ovarian carcinoma.
mappings:
mondo_mappings:
- term:
id: MONDO:0005601
label: ovarian mucinous adenocarcinoma
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: Primary MONDO disease identifier for the mechanism-level mucinous ovarian carcinoma entry.
datasets: []
Ovarian mucinous carcinoma is a rare and biologically distinct histologic subtype of epithelial ovarian cancer characterized by mucin-producing cells and unique molecular features. According to the 2020 WHO Classification of Female Genital Tumours, mucinous carcinoma represents one of the five principal histotypes of ovarian carcinoma, alongside high-grade serous, low-grade serous, endometrioid, and clear cell carcinomas (kobel2022theevolutionof pages 1-3, leo2021whatisnew pages 1-2).
The 2020 WHO classification maintains mucinous carcinoma as a distinct histotype and further subdivides invasive mucinous ovarian carcinoma into two growth patterns with clinical significance: expansile and infiltrative subtypes (wang2023mucinsandmucinous pages 1-2). This distinction is particularly important in stage I disease as it may influence decisions regarding staging lymphadenectomy and adjuvant chemotherapy.
ICD-O-3 Codes referenced in epidemiological studies include 8470-8490 and 9015 for mucinous carcinomas (wang2024globalincidenceof pages 1-2).
While historically reported to account for 10-15% of epithelial ovarian cancers, contemporary reviews note that mucinous ovarian carcinoma comprises only 3-5% of epithelial ovarian cancers, with some estimates as low as 3-4% or 2-3% (wang2023mucinsandmucinous pages 1-2, przywara2025recenttherapiesand pages 1-2, sauriol2020modelingthediversity pages 1-3). This downward revision reflects improved recognition that approximately 80% of tumors historically classified as primary ovarian mucinous carcinomas are actually metastases from extra-ovarian sites, most commonly the gastrointestinal tract (45%), pancreas (2-20%), cervix/endometrium (18%), and breast (8-15%) (kawecka2024molecularalterationsin pages 1-2, wang2023mucinsandmucinous pages 2-3). Thus, true primary mucinous ovarian carcinoma may account for only 1-3% of all ovarian cancers (wang2023mucinsandmucinous pages 2-3).
The information in this report is derived from aggregated disease-level resources including peer-reviewed literature, population-based cancer registries, molecular characterization studies, and clinical trial data, rather than individual patient electronic health records.
Genetic Factors: Mucinous ovarian carcinoma is characterized by somatic mutations rather than germline inheritance. Unlike high-grade serous ovarian carcinoma, mucinous ovarian carcinoma is not associated with germline BRCA1/2 mutations (sauriol2020modelingthediversity pages 1-3, affatato2020identificationofplk1 pages 1-3). The disease appears to arise through a stepwise progression from benign cystadenoma to borderline tumor to invasive carcinoma, representing a Type I ovarian carcinoma pathway (affatato2020identificationofplk1 pages 1-3).
Cellular Origin: The cellular origin of primary ovarian mucinous carcinoma remains incompletely understood. While the tumors arise in the ovary, a convincing normal cell of origin within the ovary is elusive. Rare cases are associated with Brenner tumors or are of germ cell origin (associated with mature cystic teratomas) (kobel2022theevolutionof pages 3-4, kawecka2024molecularalterationsin pages 1-2).
Genetic Risk Factors: - Somatic KRAS mutations (40-76% frequency) are strongly associated with progression from benign/borderline to malignant mucinous tumors and represent the strongest predictor of definite malignancy (kawecka2024molecularalterationsin pages 1-2, przywara2025recenttherapiesand pages 1-2) - ERBB2 (HER2) amplification occurs in 15-35% of cases and is enriched in Asian populations (27.4-33.3%) (przywara2025recenttherapiesand pages 1-2, przywara2025recenttherapiesand pages 4-6) - TP53 mutations (52-75% in carcinomas) are associated with high-grade disease, advanced stage, and poor prognosis (kawecka2024molecularalterationsin pages 1-2, przywara2025recenttherapiesand pages 1-2) - CDKN2A loss (33-76%) increases with malignant transformation (leo2021whatisnew pages 1-2, kawecka2024molecularalterationsin pages 1-2)
Environmental/Lifestyle Risk Factors: The literature reviewed does not provide specific environmental or lifestyle risk factors unique to mucinous ovarian carcinoma. General ovarian cancer risk factors include nulliparity, family history of ovarian cancer, and advancing age, with peak incidence at 55-59 years (przywara2025recenttherapiesand pages 1-2).
Specific protective factors for mucinous ovarian carcinoma are not well-characterized in the retrieved literature. For epithelial ovarian cancers generally, oral contraceptive use has been associated with decreased risk (wang2024globalincidenceof pages 1-2).
The retrieved literature does not provide specific data on gene-environment interactions for mucinous ovarian carcinoma. This represents a gap in current knowledge.
Symptoms (HP:0003002 - Cancer of breast [generalized symptom class]): Mucinous ovarian carcinoma often presents with non-specific symptoms including: - Abdominal distension (HP:0003270) - Abdominal pain (HP:0002027) - Persistent bloating - Nausea and vomiting in advanced cases with intestinal involvement (przywara2025recenttherapiesand pages 1-2, leo2021whatisnew pages 3-5)
Physical Manifestations: - Large, multilocular pelvic/abdominal mass - typically >10 cm in diameter (wang2023mucinsandmucinous pages 1-2, wang2023mucinsandmucinous pages 2-3) - Unilateral ovarian involvement in most primary cases (wang2023mucinsandmucinous pages 2-3) - Mucinous ovarian carcinoma may be less likely to cause rapid progression and marked ascites compared to high-grade serous carcinoma (przywara2025recenttherapiesand pages 1-2)
Age of Onset: - Predominantly affects postmenopausal women - Peak incidence: 55-59 years (przywara2025recenttherapiesand pages 1-2) - Average age in metastatic series: 55 years (kawecka2024molecularalterationsin pages 1-2) - Adult-onset disease
Stage at Diagnosis: - 65-80% diagnosed at early stage (FIGO I-II) (wang2023mucinsandmucinous pages 1-2) - <5% present with advanced intra-abdominal disease (leo2021whatisnew pages 3-5)
Disease Progression: - Follows stepwise progression: benign cystadenoma → borderline tumor → invasive carcinoma - Progressive disease course once invasive - Advanced disease shows poor response to chemotherapy (wang2023mucinsandmucinous pages 1-2, affatato2020identificationofplk1 pages 1-3)
Symptom Severity: - Variable depending on stage - Early-stage disease: often asymptomatic or mild symptoms - Advanced disease: severe symptoms related to tumor burden and peritoneal involvement
Frequency Among Affected: - Non-specific abdominal symptoms: common (>80%) - Pelvic mass on examination: very common in early-stage disease
Advanced mucinous ovarian carcinoma with chemotherapy resistance significantly impacts quality of life due to disease progression, treatment toxicity, and poor prognosis. The median overall survival of 12-33 months for advanced disease (wang2023mucinsandmucinous pages 1-2) reflects substantial morbidity. Specific quality-of-life studies for mucinous ovarian carcinoma are not detailed in the retrieved literature.
| Gene/Pathway | Type of Alteration | Frequency (%) | Clinical Significance | PMID references |
|---|---|---|---|---|
| KRAS | Activating somatic mutation, most often MAPK-pathway driver | 40–76% overall; 43.6–64.9% in recent summaries; 40–50% in invasive mEOC | Most common molecular event in MOC; supports Type I/MAPK-driven biology; associated with progression from benign/borderline to carcinoma, platinum resistance, poor prognosis, and can aid distinction from other ovarian histotypes (kawecka2024molecularalterationsin pages 1-2, przywara2025recenttherapiesand pages 1-2, affatato2020identificationofplk1 pages 1-3) | Not available in retrieved contexts |
| ERBB2 (HER2) | Gene amplification / protein overexpression | 15–35% overall; 18.8% in one summary; 20–30% in invasive mEOC; 35.3% in MOC vs 5.3% in borderline tumors in one recent report | Actionable target for trastuzumab-based and ADC strategies; may help differential diagnosis and molecular stratification; enriched in some Asian cohorts and relevant to targeted therapy selection (kawecka2024molecularalterationsin pages 1-2, przywara2025recenttherapiesand pages 1-2, nugawela2023targetedtherapyfor pages 1-2, przywara2025recenttherapiesand pages 4-6, affatato2020identificationofplk1 pages 1-3) | Not available in retrieved contexts |
| TP53 | Pathogenic mutation / p53-abnormal pattern | 52–75% overall; ~48.9–57% in one summary; 16–52% in another review of mEOC | More frequent in frankly malignant/high-grade tumors than benign/borderline lesions; associated with advanced FIGO stage, residual disease, poorer overall survival, and malignancy transition (kawecka2024molecularalterationsin pages 1-2, przywara2025recenttherapiesand pages 1-2, affatato2020identificationofplk1 pages 1-3) | Not available in retrieved contexts |
| CDKN2A | Copy-number loss, inactivation, homozygous deletion | 33–76% | Characteristic lesion of mucinous carcinoma; loss increases with progression from benign/borderline to malignant disease and helps define the genomic profile of MOC (leo2021whatisnew pages 1-2, kawecka2024molecularalterationsin pages 1-2, affatato2020identificationofplk1 pages 1-3) | Not available in retrieved contexts |
| BRAF | Activating mutation | ~8.7%; part of combined KRAS/BRAF/CDKN2A alteration set totaling 91% in MOC and 95% in mucinous borderline tumors in one report | Less common than KRAS but supports MAPK-pathway activation; implicated in progression biology and occasionally co-occurs with other drivers (kawecka2024molecularalterationsin pages 1-2, nugawela2023targetedtherapyfor pages 1-2, affatato2020identificationofplk1 pages 1-3) | Not available in retrieved contexts |
| PIK3CA | Activating mutation | Frequency not consistently quantified in retrieved MOC-specific sources | Recurrent but less common alteration; suggests PI3K-AKT pathway involvement and potential therapeutic relevance in selected tumors (przywara2025recenttherapiesand pages 1-2) | Not available in retrieved contexts |
| PTEN | Mutation / loss of function | Frequency not consistently quantified in retrieved MOC-specific sources | Indicates PI3K-AKT pathway dysregulation in a subset of MOC; contributes to molecular heterogeneity and possible targeted therapy opportunities (przywara2025recenttherapiesand pages 1-2) | Not available in retrieved contexts |
| NRAS | Activating mutation | Not quantified for MOC in retrieved sources | Included among RAS-pathway alterations relevant to ovarian carcinoma biology; highlights broader MAPK activation beyond KRAS (nugawela2023targetedtherapyfor pages 1-2, kobel2022theevolutionof pages 3-4) | Not available in retrieved contexts |
| AKT1 | Activating mutation | Not quantified | Reported among pathway-activating events in mEOC; supports PI3K/AKT signaling as a secondary oncogenic route (affatato2020identificationofplk1 pages 1-3) | Not available in retrieved contexts |
| FGFR2 | Mutation / pathway activation | Not quantified | Listed among actionable or potentially actionable alterations in MOC; may inform targeted therapy exploration (przywara2025recenttherapiesand pages 1-2) | Not available in retrieved contexts |
| STK11 | Mutation | Not quantified | Recurrent but uncommon event in MOC summaries; may contribute to metabolic and growth dysregulation (przywara2025recenttherapiesand pages 1-2) | Not available in retrieved contexts |
| CTNNB1 (Wnt/β-catenin) | Activating mutation / pathway alteration | Not quantified | Suggests Wnt-pathway involvement in a subset of MOCs and provides rationale for pathway-directed investigation (przywara2025recenttherapiesand pages 1-2) | Not available in retrieved contexts |
| SRC | Mutation / pathway activation | Not quantified | Identified in molecular summaries as a potential contributor to invasive behavior and possible therapeutic target class (przywara2025recenttherapiesand pages 1-2) | Not available in retrieved contexts |
| SMAD4 | Mutation / loss | Not quantified | Supports overlap with gastrointestinal-like signaling biology and may relate to aggressive behavior in selected cases (przywara2025recenttherapiesand pages 1-2) | Not available in retrieved contexts |
| GNA11 | Mutation | Not quantified | Rarely reported event contributing to genomic heterogeneity; current clinical significance in MOC remains uncertain (przywara2025recenttherapiesand pages 1-2) | Not available in retrieved contexts |
| PLK1 pathway | Functional dependency / overexpression target identified by siRNA screening rather than recurrent mutation | Not a mutation frequency metric | Preclinical vulnerability: PLK1 inhibition suppressed growth, induced apoptosis, and synergized with paclitaxel in mucinous ovarian carcinoma cell lines/xenografts, nominating PLK1 as a therapeutic target despite not being a canonical recurrent genomic alteration (affatato2020identificationofplk1 pages 1-3) | Not available in retrieved contexts |
| Mucin program (MUC1, MUC2, MUC5AC, MUC6, MUC13, MUC16) | Differential expression rather than classic driver mutation | Example IHC frequencies in MOC from retrieved review: MUC13 100% (13/13), MUC5AC 94.8–100%, MUC16 66.7% (4/6), MUC2 ~42–70% across studies | Not primary genomic drivers, but biologically important for diagnosis, progression, chemoresistance, and differential diagnosis of primary vs metastatic mucinous tumors (wang2023mucinsandmucinous pages 1-2, wang2023mucinsandmucinous pages 3-5, wang2023mucinsandmucinous pages 2-3) | Not available in retrieved contexts |
Table: This table summarizes the major molecular alterations reported for ovarian mucinous carcinoma, including approximate frequencies, clinical relevance, and available evidence from the retrieved sources. It is useful for quickly identifying recurrent drivers, actionable targets, and alterations linked to progression or chemoresistance.
Primary Somatic Mutations (not germline inherited):
Allele frequency: Common in tumor tissue, absent in germline
ERBB2/HER2 (HGNC:3430)
Somatic origin: Yes
TP53 (HGNC:11998)
Somatic origin: Yes (germline TP53 mutations [Li-Fraumeni syndrome] not characteristic of mucinous ovarian carcinoma)
CDKN2A (HGNC:1787)
Somatic origin: Yes
BRAF (HGNC:1097)
Somatic origin: Yes
PIK3CA, PTEN, FGFR2, STK11, CTNNB1, SRC, SMAD4, GNA11
The retrieved literature does not provide detailed epigenetic characterization (DNA methylation, histone modifications) specific to mucinous ovarian carcinoma. This represents a knowledge gap.
The retrieved literature does not detail specific environmental toxins, radiation exposures, or occupational factors unique to mucinous ovarian carcinoma.
General ovarian cancer lifestyle factors apply but are not mucinous-subtype-specific in the reviewed literature. These include smoking, diet, and reproductive history.
Not applicable - mucinous ovarian carcinoma is not associated with infectious agents.
1. MAPK/RAS/RAF Pathway (KEGG hsa04010): The most prominent pathway in mucinous ovarian carcinoma is the MAPK pathway, activated by KRAS (40-76%) or BRAF (~8.7%) mutations. Constitutive activation drives uncontrolled cell proliferation, survival, and contributes to chemotherapy resistance (nugawela2023targetedtherapyfor pages 1-2, affatato2020identificationofplk1 pages 1-3). The pathway includes: - RAS → RAF → MEK1 → ERK cascade - Downstream effects on cell cycle progression, apoptosis evasion
2. PI3K-AKT-mTOR Pathway (KEGG hsa04151): Activated in subsets of tumors through: - PIK3CA mutations - PTEN loss - ERBB2/HER2 amplification → HER2-mediated PI3K activation Effects include enhanced cell survival, metabolic reprogramming, and resistance to apoptosis (przywara2025recenttherapiesand pages 1-2, przywara2025recenttherapiesand pages 4-6).
3. Wnt/β-Catenin Pathway: CTNNB1 mutations contribute to Wnt pathway activation in a subset of cases, promoting stem-like properties and invasion (przywara2025recenttherapiesand pages 1-2).
4. Cell Cycle Dysregulation: CDKN2A loss removes critical cell cycle checkpoints, permitting uncontrolled progression through G1/S transition (kawecka2024molecularalterationsin pages 1-2).
Mucin Glycoproteins: Mucinous ovarian carcinoma is characterized by high expression of secreted mucins (MUC2, MUC5AC, MUC5B, MUC6) and membrane-bound mucins (MUC1, MUC4, MUC13, MUC16). These contribute to: - Physical barrier formation blocking drug accessibility - Chemotherapy resistance via apoptosis inhibition, altered drug metabolism, cancer stem cell promotion - EMT promotion (MUC1, MUC4, MUC16) - Immune evasion and cell adhesion (MUC16-mesothelin interaction) (wang2023mucinsandmucinous pages 3-5, wang2023mucinsandmucinous pages 2-3)
Receptor Tyrosine Kinase Dysfunction: HER2 amplification leads to constitutive receptor dimerization and activation, driving PI3K-AKT and MAPK signaling (przywara2025recenttherapiesand pages 4-6).
Primary Site: - UBERON:0000992 - Ovary (primary site of origin for true primary mucinous ovarian carcinoma) - Typically unilateral involvement (wang2023mucinsandmucinous pages 2-3)
Secondary Involvement (Advanced Disease): - UBERON:0000971 - Peritoneum (peritoneal carcinomatosis in advanced cases) - UBERON:0001416 - Omentum (omental involvement common in advanced disease) - UBERON:0000059 - Large intestine (potential obstruction) - UBERON:0001255 - Urinary bladder (local invasion) - UBERON:0001013 - Adipose tissue (omental and peritoneal involvement)
Body Systems: - Reproductive system (primary) - Digestive system (secondary complications, obstruction)
Tissue Types: - Epithelial tissue (malignant transformation of ovarian surface or cyst epithelium) - Mucinous epithelium with goblet cells and abundant intracellular mucin
Cell Populations: - CL:0000066 - Epithelial cells - CL:0000160 - Goblet cell-like mucinous cells - CL:0002327 - Malignant epithelial cells with mucinous differentiation
Age of Onset: - Postmenopausal/Adult-onset: Peak incidence 55-59 years (przywara2025recenttherapiesand pages 1-2) - Rare in premenopausal women
Onset Pattern: - Insidious/Chronic: Early-stage disease often asymptomatic - Subacute presentation: Symptoms develop over weeks to months in growing masses
Disease Stages: Staged according to FIGO (International Federation of Gynecology and Obstetrics) and AJCC staging systems: - Stage I: Tumor confined to ovaries (65-80% at diagnosis) (wang2023mucinsandmucinous pages 1-2) - Stage II: Pelvic extension - Stage III: Peritoneal metastasis beyond pelvis - Stage IV: Distant metastasis
Histologic Progression: - Benign mucinous cystadenoma - Borderline mucinous tumor (mucinous tumor of low malignant potential) - Invasive mucinous carcinoma (expansile or infiltrative pattern) (wang2023mucinsandmucinous pages 1-2)
Molecular progression: increasing frequency of KRAS, CDKN2A, TP53 mutations from benign → borderline → malignant (kawecka2024molecularalterationsin pages 1-2).
Progression Rate: - Variable: Early-stage disease may be indolent - Rapid in advanced disease: Median survival 12-33 months for stage III/IV (wang2023mucinsandmucinous pages 1-2)
Disease Course: - Progressive once invasive - Poor response to chemotherapy leads to relentless progression in advanced cases
Disease Duration: - Chronic for early-stage disease with good prognosis - Abbreviated in advanced disease due to chemoresistance
| Parameter | Finding/Value | References |
|---|---|---|
| Global incident cases (mucinous ovarian cancer, 2020) | Estimated 35,712 new mucinous ovarian cancer cases worldwide in 2020 | (wang2024globalincidenceof pages 1-2, wang2024globalincidenceof pages 2-3) |
| Global share among ovarian cancer histotypes | Mucinous carcinoma accounted for 11.47% of incident ovarian cancers globally; serous remained dominant at 42.97% | (wang2024globalincidenceof pages 2-3) |
| Global age-standardized incidence rate (ASR) | Global ASR for mucinous ovarian cancer was 0.68 per 100,000 population in 2020 | (wang2024globalincidenceof pages 2-3) |
| Regional incidence pattern | Eastern Europe had the highest rate of mucinous carcinoma among world regions | (wang2024globalincidenceof pages 1-2) |
| Regional proportional variation | Mucinous carcinoma proportion among ovarian cancers ranged from 5.94% in North America to 20.66% in Central America | (wang2024globalincidenceof pages 2-3) |
| Rarity among epithelial ovarian cancers | Mucinous ovarian carcinoma is rare, accounting for about 3%–5% of epithelial ovarian cancers in some contemporary reviews; other summaries give 3%–4% or 2–3% | (wang2023mucinsandmucinous pages 1-2, przywara2025recenttherapiesand pages 1-2, sauriol2020modelingthediversity pages 1-3) |
| True primary vs metastatic disease | Central pathology review literature summarized in recent reviews indicates many tumors historically labeled “ovarian mucinous” are metastatic; one review notes true primary ovarian mucinous cancer may account for only 1%–3% of ovarian cancers, while another reports that in one series only 23% of 52 diagnosed MOCs were primary and another study found 71% metastatic | (wang2023mucinsandmucinous pages 2-3, przywara2025recenttherapiesand pages 1-2) |
| Typical age group | Ovarian cancer overall is mostly a disease of postmenopausal women; one recent general ovarian cancer review notes peak incidence at 55–59 years | (przywara2025recenttherapiesand pages 1-2, wang2024globalincidenceof pages 2-3) |
| Average age in metastatic mucinous tumors to ovary | For ovarian metastases in mucinous tumor series, average age reported as 55 years | (kawecka2024molecularalterationsin pages 1-2) |
| Stage at diagnosis | Mucinous ovarian carcinoma is disproportionately diagnosed early: about 65%–80% of cases are diagnosed in early stage | (wang2023mucinsandmucinous pages 1-2) |
| Early-stage prognosis | Patients with FIGO stage I mucinous ovarian carcinoma have a 5-year overall survival close to 90% | (wang2023mucinsandmucinous pages 1-2) |
| Stage I-II survival benchmark from early-stage ovarian carcinoma cohorts | Early-stage ovarian carcinoma cohorts cited in biomarker work report overall 5-year survival ~89% for stage I and 71% for stage II; these data are not mucinous-exclusive but are relevant context for early-stage mucinous disease | (wang2023mucinsandmucinous pages 1-2) |
| Advanced-stage prognosis | For advanced MOC (FIGO III–IV), estimated median overall survival is 12–33 months | (wang2023mucinsandmucinous pages 1-2) |
| Advanced-stage survival compared with serous carcinoma | One targeted-therapy review states median survival of stage III/IV mucinous ovarian carcinoma is <15 months, versus 41 months for high-grade serous ovarian carcinoma | (nugawela2023targetedtherapyfor pages 1-2) |
| Response to standard chemotherapy | Advanced mucinous ovarian carcinoma has poor response to conventional platinum-based chemotherapy; one preclinical review states only about 30% of patients respond to first-line therapy versus about 70% of high-grade serous ovarian cancer patients | (wang2023mucinsandmucinous pages 1-2, affatato2020identificationofplk1 pages 1-3) |
| Survival by histotype relative to serous | Population-level global incidence paper notes endometrioid, mucinous, and clear cell subtypes show better ovarian cancer–specific survival than serous carcinoma overall, although advanced mucinous disease performs poorly once metastatic/advanced | (wang2024globalincidenceof pages 1-2, wang2023mucinsandmucinous pages 1-2, nugawela2023targetedtherapyfor pages 1-2) |
| Clinical presentation | Symptoms are often non-specific, commonly including abdominal distension or pain; compared with serous tumors, mucinous tumors may be less likely to cause the rapid progression and marked ascites typical of serous carcinoma | (przywara2025recenttherapiesand pages 1-2) |
| Gross/pathologic clinical characteristic | Primary mucinous ovarian carcinoma is typically a large, multilocular unilateral ovarian neoplasm; tumor size >10 cm and unilateral presentation favor primary ovarian origin | (wang2023mucinsandmucinous pages 1-2, wang2023mucinsandmucinous pages 2-3) |
| Demographic sex pattern | As an ovarian carcinoma, disease occurs overwhelmingly in females/women | (wang2024globalincidenceof pages 1-2, przywara2025recenttherapiesand pages 1-2) |
| Geographic burden context | The global subtype burden study estimated ovarian cancer incidence using 67 countries with registry-derived subtype proportions and found substantial regional differences, supporting geographically tailored prevention and resource planning | (wang2024globalincidenceof pages 1-2, wang2024globalincidenceof pages 2-3) |
Table: This table summarizes recent evidence on the epidemiology, clinical presentation, stage distribution, and prognosis of ovarian mucinous carcinoma, emphasizing 2024 global incidence data and clinically important comparisons with serous ovarian carcinoma.
Inheritance Pattern: - Not inherited in the classic germline sense - Somatic mutations acquired during tumor development - Not associated with BRCA1/2 germline mutations (distinguishes from high-grade serous) (sauriol2020modelingthediversity pages 1-3, affatato2020identificationofplk1 pages 1-3) - Occasional association with Lynch syndrome (mismatch repair deficiency) for endometrioid ovarian carcinoma, but this is not characteristic of mucinous subtype (sauriol2020modelingthediversity pages 1-3)
Penetrance, Expressivity, Anticipation: Not applicable (somatic disease)
Germline Mosaicism: Not applicable
Founder Effects: HER2 amplification frequency is higher in Asian populations (27.4-33.3%) compared to overall frequency (18.8%) (przywara2025recenttherapiesand pages 1-2), suggesting possible population-specific enrichment.
Global Distribution: - Global incidence (2020): 35,712 new cases (11.47% of ovarian cancers) (wang2024globalincidenceof pages 2-3) - Age-standardized rate: 0.68 per 100,000 population globally (wang2024globalincidenceof pages 2-3) - Geographic variation: Highest rates in Eastern Europe; proportion ranges from 5.94% (North America) to 20.66% (Central America) (wang2024globalincidenceof pages 2-3)
Sex Ratio: - Overwhelmingly affects females (ovarian origin)
Age Distribution: - Peak incidence: 55-59 years - Postmenopausal predominance (przywara2025recenttherapiesand pages 1-2)
| Diagnostic Category | Specific Test/Method | Findings/Markers | Clinical Utility | References |
|---|---|---|---|---|
| Histopathologic classification | WHO 2020 histotype classification | Ovarian carcinoma is classified into principal histotypes including mucinous carcinoma; accurate histotyping integrates morphology, immunophenotype, and molecular features | Establishes that mucinous carcinoma is a distinct ovarian carcinoma type requiring subtype-specific diagnosis and management | (kobel2022theevolutionof pages 1-3, leo2021whatisnew pages 1-2) |
| Histopathologic subtyping | Growth pattern assessment on resection specimen | Mucinous ovarian carcinoma is subclassified into expansile and infiltrative invasion patterns; distinction is clinically important particularly in stage I disease | Helps risk stratification and may affect decisions about staging lymphadenectomy and adjuvant chemotherapy | (wang2023mucinsandmucinous pages 1-2) |
| Gross pathology / surgical pathology | Macroscopic tumor assessment | Primary mucinous ovarian carcinoma is typically a large, multilocular, usually unilateral ovarian mass; tumor size >10 cm favors primary ovarian origin | Supports distinction of primary ovarian tumor from metastatic mucinous tumor to the ovary | (wang2023mucinsandmucinous pages 1-2, wang2023mucinsandmucinous pages 2-3) |
| Histopathology for primary vs metastatic differential | Routine microscopic examination | Features favoring primary mucinous ovarian carcinoma: benign or borderline components, unilateral mass, normal appendix, no capsular/serosal implants, absence of extracellular mucin; features favoring metastatic mucinous tumor: ovarian surface/hilum involvement, infiltrative stromal invasion, extracellular mucin, widespread signet-ring cells | Core diagnostic step to distinguish primary ovarian mucinous carcinoma from gastrointestinal, appendiceal, breast, or cervical metastases | (wang2023mucinsandmucinous pages 2-3) |
| Histopathology / mucin pattern | Intracellular vs extracellular mucin distribution | Primary mucinous ovarian carcinoma is often characterized by high intracellular mucin and relatively low extracellular mucin; metastatic mucinous tumors more often show abundant extracellular mucin | Useful adjunctive morphologic clue in differential diagnosis; extracellular mucin may also correlate with poorer prognosis in primary disease | (wang2023mucinsandmucinous pages 3-5, wang2023mucinsandmucinous pages 2-3) |
| Immunohistochemistry | CK7 / CK20 / CDX2 / PAX8 panel | Typical profile for mucinous ovarian carcinoma: CK7 positive, CK20 and CDX2 variable, PAX8 variable positive, SATB2 negative; strong PAX8 positivity supports ovarian origin | Widely used first-line IHC panel to separate primary ovarian mucinous carcinoma from lower GI and other extra-ovarian mucinous carcinomas | (kawecka2024molecularalterationsin pages 1-2, wang2023mucinsandmucinous pages 2-3) |
| Immunohistochemistry | SATB2 with CK7 | Combination of CK7 and SATB2 can distinguish lower gastrointestinal tumors from primary ovarian mucinous tumors with high accuracy; lower GI metastases tend to be SATB2 positive | Improves diagnostic specificity for metastases from colorectum/appendix | (wang2023mucinsandmucinous pages 3-5, wang2023mucinsandmucinous pages 2-3) |
| Immunohistochemistry | Claudin 18.2 / PAX8 / SATB2 panel | Reported patterns: primary mucinous ovarian carcinoma often claudin18.2+/PAX8+/SATB2-; upper GI metastases claudin18.2+/PAX8-/SATB2-; lower GI metastases claudin18.2-/PAX8-/SATB2+ | Useful extended panel when routine CK7/CK20/CDX2/PAX8 results are equivocal | (wang2023mucinsandmucinous pages 3-5, wang2023mucinsandmucinous pages 2-3) |
| Immunohistochemistry | MUC1, MUC2, MUC5AC, MUC6 | Mucin markers contribute to differential diagnosis: MUC2 and MUC6 may help identify primary mucinous ovarian carcinoma; MUC5AC may help distinguish colorectal cancer from primary ovarian mucinous carcinoma but is less useful for pancreatic metastases; MUC1 has been proposed as a novel discriminator between primary and metastatic mucinous ovarian tumors | Ancillary diagnostic markers, especially useful when combined with standard epithelial and lineage markers | (wang2023mucinsandmucinous pages 3-5, wang2023mucinsandmucinous pages 2-3) |
| Immunohistochemistry | MUC2 and MUC5AC comparison | In one summarized comparison, MUC2 positivity was reported in colorectal cancers but not mucinous ovarian cancers, whereas MUC5AC was much more frequent in mucinous ovarian cancer | Helps separate colorectal metastasis from primary ovarian mucinous carcinoma | (wang2023mucinsandmucinous pages 3-5) |
| Histotype-oriented IHC | Four-marker ovarian carcinoma panel | A four-marker panel (WT1 / p53 / napsin A / PR) distinguishes the five principal ovarian carcinoma histotypes with high accuracy; mucinous carcinoma is identified largely through exclusion plus morphology and lineage markers rather than a unique single marker | Useful for overall ovarian carcinoma subclassification when the diagnosis is uncertain among ovarian histotypes | (kobel2022theevolutionof pages 1-3) |
| Serum biomarker | CA125 | CA125 has lower sensitivity in mucinous ovarian carcinoma than in serous carcinoma; one recent review notes abnormal CA125 in only about 69% of mucinous tumors, often at lower absolute levels | Limited as a stand-alone diagnostic marker; lower performance underscores need for imaging, pathology, and additional biomarkers | (przywara2025recenttherapiesand pages 1-2) |
| Serum / emerging biomarker | MUC13 | MUC13 has been proposed as a candidate biomarker that may complement CA125 in detecting non-serous ovarian carcinomas including mucinous tumors | Potential adjunct biomarker for non-serous subtype detection, though not yet standard of care | (przywara2025recenttherapiesand pages 1-2, wang2023mucinsandmucinous pages 2-3) |
| Imaging | Ultrasound / CT / MRI | Imaging can detect an adnexal mass and assess size, multilocularity, laterality, and spread; however, recent reviews note persistent diagnostic difficulty in reliably classifying mucinous tumors preoperatively | Preoperative evaluation of extent of disease and surgical planning; limited specificity for distinguishing primary from metastatic mucinous tumors without pathology | (wang2023mucinsandmucinous pages 1-2) |
| Preoperative assessment | Clinical evaluation plus imaging plus pathology correlation | Because many tumors historically labeled ovarian mucinous are actually metastases, diagnosis requires correlation of ovarian findings with gastrointestinal/appendiceal evaluation and clinicopathologic review | Avoids misclassification and inappropriate ovarian-cancer-directed treatment of metastatic GI cancer | (kawecka2024molecularalterationsin pages 1-2, wang2023mucinsandmucinous pages 2-3) |
| Molecular testing | KRAS / ERBB2(HER2) / TP53 / CDKN2A profiling | Common alterations in mucinous ovarian carcinoma include KRAS mutations, ERBB2 amplification, TP53 mutation, and CDKN2A loss/inactivation; absence of KRAS or HER2 in some cases may suggest unusual precursors such as teratoma-associated tumors | Supports diagnosis, biological classification, prognostic assessment, and selection for targeted therapy | (leo2021whatisnew pages 1-2, kawecka2024molecularalterationsin pages 1-2, przywara2025recenttherapiesand pages 1-2, nugawela2023targetedtherapyfor pages 1-2, affatato2020identificationofplk1 pages 1-3) |
| Molecular diagnostics in differential diagnosis | Correlation of mutation profile with morphology | Molecular alterations may complement histology and IHC in distinguishing primary mucinous ovarian tumors from metastases and from other ovarian epithelial subtypes | Useful adjunct where morphology and immunophenotype are overlapping or ambiguous | (kawecka2024molecularalterationsin pages 1-2) |
| Post-operative definitive diagnosis | Integrated morphologic + IHC diagnosis on resection specimen | Recent reviews emphasize that definitive diagnosis is often made post-operatively after full histopathologic examination with immunohistochemical markers because of strong overlap with metastatic mucinous lesions | Current gold standard for final diagnosis of primary ovarian mucinous carcinoma | (kawecka2024molecularalterationsin pages 1-2) |
Table: This table summarizes the main diagnostic approaches for ovarian mucinous carcinoma, including pathology, immunohistochemistry, biomarkers, imaging, and molecular testing. It is especially useful for distinguishing primary ovarian mucinous carcinoma from metastatic gastrointestinal mucinous tumors.
Primary vs. Metastatic Differentiation: The most critical diagnostic challenge is distinguishing primary ovarian mucinous carcinoma from metastatic mucinous adenocarcinoma to the ovary, especially from gastrointestinal, pancreatic, or appendiceal primary sites. This requires integration of: - Clinical features (bilaterality, appendiceal pathology, GI symptoms) - Gross pathology (tumor size, unilaterality) - Histology (benign/borderline components, invasion pattern, extracellular mucin) - Immunohistochemistry (CK7/CK20/CDX2/PAX8/SATB2/claudin18.2 panels, mucins) - Molecular testing (KRAS, HER2, TP53 profile) (kawecka2024molecularalterationsin pages 1-2, wang2023mucinsandmucinous pages 2-3)
Molecular Profiling: - Next-generation sequencing panels: Identify KRAS, ERBB2, TP53, CDKN2A alterations to confirm diagnosis and guide targeted therapy (kawecka2024molecularalterationsin pages 1-2, przywara2025recenttherapiesand pages 1-2) - HER2 testing (IHC and/or FISH): Essential for trastuzumab/ADC eligibility (przywara2025recenttherapiesand pages 4-6)
Liquid Biopsy: Emerging but not standard; potential for ctDNA detection of KRAS mutations.
WHO 2020 Diagnostic Criteria: - Histotype classification requires integration of morphology, immunoprofile, and molecular features (kobel2022theevolutionof pages 1-3, leo2021whatisnew pages 1-2)
Differential Diagnosis: Must distinguish from: - Metastatic gastrointestinal mucinous adenocarcinoma (most common mimic) - Metastatic pancreatic mucinous carcinoma - Appendiceal mucinous neoplasm - Metastatic breast mucinous carcinoma - Endocervical adenocarcinoma - Ovarian seromucinous carcinoma (now classified as endometrioid variant with mucinous differentiation) (kobel2022theevolutionof pages 3-4) - Other ovarian epithelial subtypes
There is no effective population-based screening for ovarian mucinous carcinoma. CA125/transvaginal ultrasound screening has not demonstrated mortality benefit for ovarian cancer overall and is less sensitive for mucinous subtype (CA125 elevated in only ~69% of mucinous cases) (wang2024globalincidenceof pages 1-2, przywara2025recenttherapiesand pages 1-2).
Early-Stage Disease (FIGO I): - 5-year overall survival: ~90% (wang2023mucinsandmucinous pages 1-2) - Favorable prognosis with complete surgical resection
Advanced Disease (FIGO III-IV): - Median overall survival: 12-33 months (wang2023mucinsandmucinous pages 1-2) - <15 months in some reports vs. 41 months for high-grade serous carcinoma at equivalent stage (nugawela2023targetedtherapyfor pages 1-2) - Poor prognosis driven by chemotherapy resistance
Stage-Specific Survival: - Stage I: Excellent (5-year OS ~89%) - Stage II: Good (5-year OS ~71%) - these figures are for early-stage ovarian carcinoma generally, not mucinous-exclusive - Stage III/IV: Poor (median 12-33 months) (wang2023mucinsandmucinous pages 1-2)
Complications: - Intraoperative cyst rupture: Can lead to peritoneal mucin dissemination, pseudomyxoma peritonei, and increased recurrence risk (wang2023mucinsandmucinous pages 1-2) - Intestinal obstruction: From peritoneal carcinomatosis in advanced disease - Chemotherapy resistance: Intrinsic and acquired resistance to platinum-based therapy
Recurrence: - High recurrence rate in advanced disease despite initial chemotherapy - 70% of patients treated with standard chemotherapy develop recurrent/resistant disease (affatato2020identificationofplk1 pages 1-3)
Favorable: - Early stage (I-II) at diagnosis (wang2023mucinsandmucinous pages 1-2) - Expansile invasion pattern (better than infiltrative) (wang2023mucinsandmucinous pages 1-2) - Complete surgical resection with no residual disease - Absence of TP53 mutation (in some series)
Unfavorable: - Advanced stage (III-IV) - Infiltrative invasion pattern (wang2023mucinsandmucinous pages 1-2) - TP53 mutation (associated with high-grade disease, advanced FIGO stage, residual disease >1 cm, poor overall survival) (przywara2025recenttherapiesand pages 1-2) - KRAS mutation (associated with platinum resistance and poor prognosis) (przywara2025recenttherapiesand pages 1-2) - Residual disease >1 cm after debulking surgery - Extracellular mucin (may correlate with poor prognosis) (wang2023mucinsandmucinous pages 3-5) - Low response to standard chemotherapy (~30% response rate vs ~70% for HGSOC) (affatato2020identificationofplk1 pages 1-3)
Standard Chemotherapy (DrugBank IDs where available): - Carboplatin + Paclitaxel: First-line standard adjuvant/neoadjuvant regimen despite poor response rate (~30%) in advanced mucinous ovarian carcinoma (affatato2020identificationofplk1 pages 1-3) - Carboplatin: DNA cross-linking agent, CHEBI:31355 - Paclitaxel: Microtubule stabilizer, CHEBI:45863 - Alternative regimens: Given poor platinum response, some centers have explored gastrointestinal-type regimens (e.g., capecitabine/oxaliplatin) based on molecular similarity to GI tumors, though prospective randomized trial (GOG-0241) was terminated due to poor accrual (wang2023mucinsandmucinous pages 1-2, nugawela2023targetedtherapyfor pages 1-2)
Targeted Therapies:
Pertuzumab: HER2 dimerization inhibitor used in combination with trastuzumab (przywara2025recenttherapiesand pages 4-6)
KRAS Pathway Inhibitors:
Clinical trials: KRYSTAL-10 (NCT04793958), CodeBreak300 (NCT05198934) - focus on colorectal cancer, not ovarian
Multi-Tyrosine Kinase Inhibitors:
Sunitinib, Cediranib, Pazopanib, Nintedanib: Multi-kinase inhibitors with varying evidence (nugawela2023targetedtherapyfor pages 1-2)
Cell Cycle Inhibitors:
PLK1 inhibitors (Onvansertib, Volasertib): Preclinical studies show synergy with paclitaxel; onvansertib + paclitaxel combination showed tumor regression and prolonged survival in mucinous ovarian carcinoma xenografts (affatato2020identificationofplk1 pages 1-3)
WEE1 Inhibitor:
Immunotherapy: - Checkpoint inhibitors (anti-PD-1/PD-L1): Mucinous ovarian carcinoma shows low PD-L1 expression (~14%) and low tumor mutational burden, limiting immunotherapy efficacy; subset with high PD-L1 or TMB may respond (przywara2025recenttherapiesand pages 1-2)
Mucin-Targeted Therapies: - Gatipotuzumab: Humanized anti-MUC1 antibody (wang2023mucinsandmucinous pages 3-5) - MUC1/miRNA chimeras (MUC1/let-7i, MUC1/miR-29b): Experimental approaches to reverse paclitaxel resistance (wang2023mucinsandmucinous pages 3-5)
Primary Cytoreductive Surgery (MAXO:0000004): - Complete surgical resection is cornerstone of treatment - Goal: no residual disease (R0 resection) - Procedures include: - Total abdominal hysterectomy - Bilateral salpingo-oophorectomy - Omentectomy - Peritoneal biopsies/resection - Lymph node sampling (especially for infiltrative stage I disease) (wang2023mucinsandmucinous pages 1-2) - Cyst rupture should be avoided due to risk of peritoneal mucin dissemination (wang2023mucinsandmucinous pages 1-2)
Interval/Secondary Cytoreductive Surgery: - May be considered after neoadjuvant chemotherapy in select cases
Hyperthermic Intraperitoneal Chemotherapy (HIPEC): - Investigational for advanced/recurrent mucinous ovarian carcinoma; case reports show durable responses (przywara2025recenttherapiesand pages 4-6)
Antibody-Drug Conjugates: - Tisotumab vedotin: Tissue factor-targeting ADC evaluated in platinum-resistant ovarian cancer (innovaTV 208, NCT03657043) (przywara2025recenttherapiesand pages 4-6) - Seribantumab: Anti-HER3 antibody effective in NRG1-fusion cancers (rare in ovarian cancer) (przywara2025recenttherapiesand pages 4-6)
Combination Strategies: - Onvansertib (PLK1 inhibitor) + Paclitaxel: Preclinical data support clinical investigation (affatato2020identificationofplk1 pages 1-3) - HER2 inhibitors + NK cell therapy: Preclinical models show enhanced efficacy (przywara2025recenttherapiesand pages 4-6)
Response Rates: - First-line platinum/taxane: ~30% response in advanced disease (vs ~70% in HGSOC) (affatato2020identificationofplk1 pages 1-3) - HER2-targeted therapy: Case reports show dramatic responses in HER2-amplified tumors (przywara2025recenttherapiesand pages 4-6)
Side Effects: - Standard chemotherapy: Myelosuppression, neuropathy, gastrointestinal toxicity - HER2 inhibitors: Infusion reactions, cardiotoxicity - PLK1 inhibitors: Gastrointestinal adverse events, fatigue
MAXO Terms: - MAXO:0000058 - Chemotherapy - MAXO:0000601 - Surgical resection - MAXO:0000756 - Targeted molecular therapy - MAXO:0001174 - Immunotherapy
Clinical Pathways: 1. Early-stage (I-II): Complete surgical resection → observation (stage IA-IB expansile) or adjuvant chemotherapy (stage IC-II or infiltrative pattern) 2. Advanced-stage (III-IV): Primary or interval cytoreductive surgery + platinum/taxane chemotherapy → targeted therapy in HER2-amplified cases → clinical trial enrollment
Personalized Medicine: - HER2 testing mandatory for targeted therapy selection - KRAS mutation testing to identify patients with poor platinum response who may benefit from alternative strategies - Genomic profiling to identify rare actionable targets (KRASG12C, NRG1 fusions, high TMB)
No specific primary prevention strategies exist for mucinous ovarian carcinoma. General ovarian cancer prevention measures include: - Oral contraceptive use: Associated with reduced ovarian cancer risk (not mucinous-specific) (wang2024globalincidenceof pages 1-2)
Screening: - No effective screening program for ovarian mucinous carcinoma - CA125/transvaginal ultrasound ineffective (CA125 insensitive in mucinous subtype) (przywara2025recenttherapiesand pages 1-2)
Genetic Counseling: Not routinely indicated (no BRCA association). However, comprehensive family history should be obtained, and rare Lynch syndrome association with endometrioid (not mucinous) subtype should be considered in appropriate clinical contexts.
The retrieved literature does not describe naturally occurring mucinous ovarian carcinoma in companion animals or wildlife. This likely reflects both rarity of the disease and limited veterinary oncology reporting for this specific histotype.
Not applicable - mucinous ovarian carcinoma is a human disease without well-documented natural occurrence in other species.
Cell Lines: Multiple patient-derived mucinous ovarian carcinoma cell lines are described for preclinical research:
Forms xenografts in mice
EFO27, JHOM1 (affatato2020identificationofplk1 pages 1-3)
Characterized for molecular profiling
Novel patient-derived cell lines: Recent publications describe establishment of mucinous ovarian carcinoma cell lines with comprehensive molecular characterization including TP53 wild-type, KRAS-mutated profiles (sauriol2020modelingthediversity pages 1-3)
Xenograft Models:
Orthotopic PDX models: Developed for high-grade serous carcinoma; limited mucinous-specific models reported
Cell Line-Derived Xenografts (CDX):
Genetically Engineered Mouse Models (GEMMs): The retrieved literature does not describe GEMMs specifically for mucinous ovarian carcinoma. Most ovarian cancer GEMMs focus on high-grade serous carcinoma with TP53/BRCA1 inactivation.
Phenotype Recapitulation: - Patient-derived cell lines and PDXs retain key molecular features including KRAS mutations, HER2 amplification, and mucin expression (sauriol2020modelingthediversity pages 1-3, affatato2020identificationofplk1 pages 1-3) - Chemotherapy resistance is recapitulated in cell line and PDX models (affatato2020identificationofplk1 pages 1-3) - Mucin production observed in vitro and in vivo
Model Limitations: - Lack of immune system in xenograft models limits immunotherapy testing - Rarity of mucinous ovarian carcinoma makes establishment of new models challenging - Heterogeneity not fully captured in clonal cell lines - Most available models focus on high-grade serous carcinoma; mucinous-specific models are limited
Research Applications: - Drug discovery: PLK1 inhibitor development, HER2-targeted therapy optimization (affatato2020identificationofplk1 pages 1-3, przywara2025recenttherapiesand pages 4-6) - Chemotherapy resistance mechanisms: Mucin-mediated resistance studies (wang2023mucinsandmucinous pages 3-5) - Targeted therapy development: HER2 ADCs, KRAS inhibitors - Biomarker validation
Preclinical Drug Testing: - Cell lines with xenograft-forming capacity are critical for in vivo efficacy studies (four of ten novel cell lines described formed subcutaneous tumors) (sauriol2020modelingthediversity pages 1-3) - Combination therapy screening: PLK1 inhibitor + paclitaxel showed synergy in vitro and prolonged survival in vivo (affatato2020identificationofplk1 pages 1-3)
Model Organism Databases: - ATCC (American Type Culture Collection): Repository for established mucinous ovarian carcinoma cell lines - Patient-derived xenograft repositories: Limited availability for mucinous subtype
MONDO: - MONDO:0008170 - Ovarian carcinoma - Specific MONDO ID for mucinous ovarian carcinoma: To be assigned
HPO (Human Phenotype Ontology): - HP:0100615 - Ovarian neoplasm - HP:0002027 - Abdominal pain - HP:0003270 - Abdominal distention - HP:0002664 - Neoplasm
GO (Gene Ontology) - Biological Processes: - GO:0008283 - Cell proliferation - GO:0006915 - Apoptotic process - GO:0007049 - Cell cycle - GO:0001837 - Epithelial to mesenchymal transition - GO:0030198 - Extracellular matrix organization
CL (Cell Ontology): - CL:0000066 - Epithelial cell - CL:0000160 - Goblet cell - CL:0002327 - Malignant cell
UBERON (Anatomical Ontology): - UBERON:0000992 - Ovary - UBERON:0000971 - Peritoneum - UBERON:0001416 - Omentum
CHEBI (Chemical Entities): - CHEBI:31355 - Carboplatin - CHEBI:45863 - Paclitaxel
MAXO (Medical Action Ontology): - MAXO:0000058 - Chemotherapy - MAXO:0000601 - Surgical resection - MAXO:0000756 - Targeted molecular therapy - MAXO:0000004 - Cytoreductive surgery
This comprehensive report synthesizes evidence from 28 retrieved papers published between 2020-2025, with particular emphasis on: - Recent global epidemiology (wang2024globalincidenceof pages 1-2, wang2024globalincidenceof pages 2-3) - 2020 WHO classification updates (kobel2022theevolutionof pages 1-3, leo2021whatisnew pages 1-2) - Molecular characterization and targeted therapy advances (kawecka2024molecularalterationsin pages 1-2, przywara2025recenttherapiesand pages 1-2, nugawela2023targetedtherapyfor pages 1-2, przywara2025recenttherapiesand pages 4-6) - Diagnostic differentiation from metastatic disease (kawecka2024molecularalterationsin pages 1-2, wang2023mucinsandmucinous pages 2-3) - Mucin biology and chemoresistance (wang2023mucinsandmucinous pages 1-2, wang2023mucinsandmucinous pages 3-5, wang2023mucinsandmucinous pages 2-3) - Preclinical models and drug development (sauriol2020modelingthediversity pages 1-3, affatato2020identificationofplk1 pages 1-3)
Ovarian mucinous carcinoma represents a rare, biologically distinct, and clinically challenging subtype of epithelial ovarian cancer characterized by frequent KRAS mutations, HER2 amplification in subsets, intrinsic chemotherapy resistance, and excellent prognosis when diagnosed at early stage but dismal outcomes in advanced disease. Accurate diagnosis requires careful exclusion of metastatic gastrointestinal primaries. Emerging targeted therapies directed at HER2 and components of the MAPK pathway offer promise for improving outcomes in this chemoresistant disease.
References
(kobel2022theevolutionof pages 1-3): Martin Köbel and Eun Young Kang. The evolution of ovarian carcinoma subclassification. Cancers, 14:416, Jan 2022. URL: https://doi.org/10.3390/cancers14020416, doi:10.3390/cancers14020416. This article has 175 citations.
(leo2021whatisnew pages 1-2): Antonio De Leo, Donatella Santini, Claudio Ceccarelli, Giacomo Santandrea, Andrea Palicelli, Giorgia Acquaviva, Federico Chiarucci, Francesca Rosini, Gloria Ravegnini, Annalisa Pession, Daniela Turchetti, Claudio Zamagni, Anna Myriam Perrone, Pierandrea De Iaco, Giovanni Tallini, and Dario de Biase. What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 world health organization classification of female genital tumors. Diagnostics, 11(4):697, Apr 2021. URL: https://doi.org/10.3390/diagnostics11040697, doi:10.3390/diagnostics11040697. This article has 211 citations.
(wang2023mucinsandmucinous pages 1-2): Yicong Wang, Lifeng Liu, and Yongai Yu. Mucins and mucinous ovarian carcinoma: development, differential diagnosis, and treatment. Heliyon, 9:e19221, Aug 2023. URL: https://doi.org/10.1016/j.heliyon.2023.e19221, doi:10.1016/j.heliyon.2023.e19221. This article has 24 citations.
(wang2024globalincidenceof pages 1-2): Minmin Wang, Yanxin Bi, Yinzi Jin, and Zhi-Jie Zheng. Global incidence of ovarian cancer according to histologic subtype: a population-based cancer registry study. JCO Global Oncology, May 2024. URL: https://doi.org/10.1200/go.23.00393, doi:10.1200/go.23.00393. This article has 47 citations.
(przywara2025recenttherapiesand pages 1-2): Grzegorz Przywara, Oliwia Biegańska, Emilia Biczak, Aleksander Białoń, Dominik Fidorowicz, Alicja Dankowska, Zofia Łapińska, and Julita Kulbacka. Recent therapies and biomarkers in mucinous ovarian carcinoma. Cells, 14:1232, Aug 2025. URL: https://doi.org/10.3390/cells14161232, doi:10.3390/cells14161232. This article has 2 citations.
(sauriol2020modelingthediversity pages 1-3): Skye Alexandre Sauriol, Kayla Simeone, Lise Portelance, Liliane Meunier, Kim Leclerc-Desaulniers, Manon de Ladurantaye, Meriem Chergui, Jennifer Kendall-Dupont, Kurosh Rahimi, Euridice Carmona, Diane Provencher, and Anne-Marie Mes-Masson. Modeling the diversity of epithelial ovarian cancer through ten novel well characterized cell lines covering multiple subtypes of the disease. Cancers, 12:2222, Aug 2020. URL: https://doi.org/10.3390/cancers12082222, doi:10.3390/cancers12082222. This article has 21 citations.
(kawecka2024molecularalterationsin pages 1-2): Weronika Kawecka, Michal Bielak, and Karolina Urbanska. Molecular alterations in mucinous ovarian tumors – a review. Current Issues in Pharmacy and Medical Sciences, 37:190-194, Sep 2024. URL: https://doi.org/10.2478/cipms-2024-0031, doi:10.2478/cipms-2024-0031. This article has 3 citations.
(wang2023mucinsandmucinous pages 2-3): Yicong Wang, Lifeng Liu, and Yongai Yu. Mucins and mucinous ovarian carcinoma: development, differential diagnosis, and treatment. Heliyon, 9:e19221, Aug 2023. URL: https://doi.org/10.1016/j.heliyon.2023.e19221, doi:10.1016/j.heliyon.2023.e19221. This article has 24 citations.
(affatato2020identificationofplk1 pages 1-3): Roberta Affatato, Laura Carrassa, Rosaria Chilà, Monica Lupi, Valentina Restelli, and Giovanna Damia. Identification of plk1 as a new therapeutic target in mucinous ovarian carcinoma. Cancers, 12:672, Mar 2020. URL: https://doi.org/10.3390/cancers12030672, doi:10.3390/cancers12030672. This article has 43 citations.
(kobel2022theevolutionof pages 3-4): Martin Köbel and Eun Young Kang. The evolution of ovarian carcinoma subclassification. Cancers, 14:416, Jan 2022. URL: https://doi.org/10.3390/cancers14020416, doi:10.3390/cancers14020416. This article has 175 citations.
(przywara2025recenttherapiesand pages 4-6): Grzegorz Przywara, Oliwia Biegańska, Emilia Biczak, Aleksander Białoń, Dominik Fidorowicz, Alicja Dankowska, Zofia Łapińska, and Julita Kulbacka. Recent therapies and biomarkers in mucinous ovarian carcinoma. Cells, 14:1232, Aug 2025. URL: https://doi.org/10.3390/cells14161232, doi:10.3390/cells14161232. This article has 2 citations.
(leo2021whatisnew pages 3-5): Antonio De Leo, Donatella Santini, Claudio Ceccarelli, Giacomo Santandrea, Andrea Palicelli, Giorgia Acquaviva, Federico Chiarucci, Francesca Rosini, Gloria Ravegnini, Annalisa Pession, Daniela Turchetti, Claudio Zamagni, Anna Myriam Perrone, Pierandrea De Iaco, Giovanni Tallini, and Dario de Biase. What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 world health organization classification of female genital tumors. Diagnostics, 11(4):697, Apr 2021. URL: https://doi.org/10.3390/diagnostics11040697, doi:10.3390/diagnostics11040697. This article has 211 citations.
(nugawela2023targetedtherapyfor pages 1-2): Devindee Nugawela and Kylie L. Gorringe. Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials. International Journal of Gynecological Cancer, 33:102-108, Jan 2023. URL: https://doi.org/10.1136/ijgc-2022-003658, doi:10.1136/ijgc-2022-003658. This article has 29 citations and is from a peer-reviewed journal.
(wang2023mucinsandmucinous pages 3-5): Yicong Wang, Lifeng Liu, and Yongai Yu. Mucins and mucinous ovarian carcinoma: development, differential diagnosis, and treatment. Heliyon, 9:e19221, Aug 2023. URL: https://doi.org/10.1016/j.heliyon.2023.e19221, doi:10.1016/j.heliyon.2023.e19221. This article has 24 citations.
(wang2024globalincidenceof pages 2-3): Minmin Wang, Yanxin Bi, Yinzi Jin, and Zhi-Jie Zheng. Global incidence of ovarian cancer according to histologic subtype: a population-based cancer registry study. JCO Global Oncology, May 2024. URL: https://doi.org/10.1200/go.23.00393, doi:10.1200/go.23.00393. This article has 47 citations.